MedIntegrity, Decididos a no olvidar, hasta el final para resaltar.
Hogar/ Noticias/ PIC/S PI 058-1 Explained: Key Updates and Interpretations of the 2022 EU GMP Annex 1

PIC/S PI 058-1 Explained: Key Updates and Interpretations of the 2022 EU GMP Annex 1

Tabla de contenido

    The official interpretation document for the 2022 version of Annex 1 on the Manufacture of Sterile Medicinal Products is now available.

    On October 28, 2026, the Pharmaceutical Inspection Co-operation Scheme (PIC/S) officially published PI 058-1, Interpretation of the Most Important Changes in the Annex 1 on the Manufacture of Sterile Products (2022). The document was drafted and jointly adopted by the Annex 1 Implementation Working Group (A1IWG), involving experts from PIC/S, the European Medicines Agency (EMA), and the World Health Organization (WHO). Presented in a question-and-answer (Q&A) format, it addresses key technical issues that have generated differing interpretations since the implementation of the 2022 version of Annex 1.

    What Is PI 058-1 and What Is Its Purpose?

    Officially published by PIC/S on October 28, 2026, PI 058-1 is an important regulatory guidance document for sterile medicinal product manufacturers, quality management professionals, and pharmaceutical testing instrument manufacturers.

    Its primary purpose is to clarify how certain important provisions of the 2022 version of Annex 1: Manufacture of Sterile Medicinal Products (hereinafter referred to as Annex 1) should be interpreted and implemented, particularly those technical issues that have been subject to different interpretations in practice.

    One important distinction should be made: PI 058-1 is not a new GMP regulation, nor is it a further revision of Annex 1. Instead, it uses a Q&A format to promote a consistent understanding of existing requirements among regulatory authorities and the pharmaceutical industry. It does not introduce additional GMP requirements. The document became effective on October 28, 2026.

    Developed with the participation of relevant experts from PIC/S, EMA, and WHO, the document reflects the further clarification of key technical issues by international regulatory authorities following a period of implementation of the 2022 version of Annex 1.

    Key Topics and Technical Interpretations in PI 058-1

    The original English PDF of PI 058-1, published on the PIC/S official website, consists of 29 pages. Its main content is presented in a Q&A format and follows the chapter structure of the 2022 version of Annex 1.

    Among its contents, Sections 8 and 9 address particularly concentrated technical issues. These sections are also closely related to sterile pharmaceutical manufacturing, Filter Integrity Testing, Container Closure Integrity Testing (CCIT), and Single-Use Systems (SUS).

    1. Pharmaceutical Water: Online TOC Monitoring Does Not Replace Comprehensive Offline Water Quality Monitoring

    This section is particularly relevant to pharmaceutical water monitoring and TOC testing systems.

    PI 058-1 addresses a practical question: If a Water for Injection (WFI) return loop is already equipped with online TOC and conductivity monitoring systems, is offline sampling and testing still necessary?

    The answer is yes.

    The reason is that online monitoring generally focuses on TOC and conductivity and cannot replace comprehensive monitoring of other water quality parameters.

    The document specifically highlights the following points:

    • WFI return points should also be included in the offline monitoring program.

    • Offline monitoring should consider parameters beyond those covered by online TOC and conductivity monitoring.

    • These include microbiological contamination and bacterial endotoxins.

    • Sampling plans should be established based on risk assessments.

    In addition, the document clarifies several important details.

    ① WFI Sampling Frequency

    For WFI used in production, samples should be collected at least every working day from one representative point of use (POU), with both chemical and microbiological testing performed.

    The representative sampling point should be selected based on a risk assessment. Consideration should also be given to whether worst-case sampling points need to be tested every working day.

    ② WFI Circulation Temperature

    Continuous circulation at temperatures above 70°C is a highly recommended and well-established approach, but it is not the only acceptable option.

    If a lower-temperature circulation system is used, including ambient-temperature or cold circulation systems, more stringent disinfection, sanitization, and monitoring measures are required to control microbiological risks.

    These measures may include increasing disinfection frequency, expanding the sampling program, or tightening internal bioburden alert limits.

    ③ Process Gas Monitoring

    For process gases used in production, microbiological monitoring at points of use should be performed at an increased frequency based on risk.

    Other parameters that may affect gas quality, such as oil and moisture content, should also be adequately monitored.

    One particularly important point is that PI 058-1 does not diminish the value of online TOC monitoring. Rather, it further clarifies the complementary relationship between online monitoring and offline testing.

    Online TOC monitoring helps manufacturers continuously track changes in organic carbon levels within water systems. However, it does not eliminate the need for a comprehensive chemical and microbiological monitoring program.

    2. Production and Filtration Systems: Further Clarification of PUPSIT Requirements

    PUPSIT stands for Pre-Use Post-Sterilization Integrity Testing.

    Its purpose is to verify filter integrity after sterilization but before the filter is used for product filtration.

    The document provides clarification on several long-standing questions raised by pharmaceutical manufacturers.

    1. Must PUPSIT Be Performed on All Sterilizing-Grade Filters?

    No.

    The document clarifies that PUPSIT should be performed, where feasible, on filters used for the sterilizing filtration of the final product.

    For sterilizing-grade filters used for other purposes during manufacturing, such as upstream bioburden reduction, PUPSIT is not a mandatory requirement. However, appropriate integrity testing measures should still be established based on risk assessments and the Contamination Control Strategy (CCS).

    This means that manufacturers should not apply identical PUPSIT requirements to all sterilizing-grade filters without distinction. Instead, the specific purpose and process location of each filter should be considered.

    2. Under What Circumstances Can PUPSIT Be Omitted?

    The document allows alternative approaches to be considered when PUPSIT genuinely cannot be implemented, but strict conditions apply.

    First, manufacturers should prioritize process design modifications or equipment upgrades to enable PUPSIT.

    Alternative approaches may only be considered when there are objective limitations inherent to the process itself, rather than limitations resulting from inadequate equipment design.

    In addition, manufacturers must:

    • Clearly document the justification in the CCS.

    • Conduct a comprehensive risk assessment focused on product and patient safety.

    • Establish appropriate risk mitigation measures.

    • Provide sufficient scientific justification and supporting evidence.

    The document also emphasizes that risk assessments must not be used inappropriately as a justification for omitting PUPSIT.

    3. Is PUPSIT Required for Both Filters in a Dual-Filter System?

    The document provides a clear interpretation.

    If both the primary filter and the backup filter are declared as potentially supporting batch release, both should undergo PUPSIT.

    If the backup filter has not undergone PUPSIT, it cannot be used to demonstrate that effective sterilizing filtration has been achieved for the batch in the event that the post-use integrity test of the primary filter fails.

    This clarification has direct implications for sterile filtration processes using two filters in series.

    4. Filter Integrity Testing Is Not Limited to Pre-Use Testing

    This requirement should also be understood in conjunction with Section 8.87 of Annex 1, which requires the integrity of sterilizing-grade filters to be verified before use and after use.

    PUPSIT addresses the verification of filter integrity after sterilization and before use. Post-use integrity testing, on the other hand, helps confirm whether the filter maintained its integrity throughout the actual filtration process.

    Together, these two tests form an important part of filter integrity control.

    For pharmaceutical manufacturers, Filter Integrity Testing is therefore not merely an equipment operation. It is also an essential component of sterile filtration process validation and batch quality control.

    3. Container Closure Integrity Testing: Further Clarification of CCIT Scope and Testing Frequency

    This section mainly addresses two questions.

    1. Is 100% Integrity Testing Required for Small-Volume Flexible Infusion Bags?

    Yes.

    The document provides clarification regarding flexible infusion bags with a capacity of less than 100 mL.

    Even if the final closure uses a non-fusion method, such as an adhesive port or a stopper inserted and secured with a cap, 100% integrity testing is required under Section 8.22 of Annex 1, provided that the bag body itself is formed by fusion welding.

    This means that manufacturers cannot determine whether 100% integrity testing is required solely based on the closure method used for the final package.

    2. Is Batch-by-Batch CCIT Required for Products Using Non-Fusion Closure Methods?

    The document states that these products should undergo CCIT using a validated method suitable for the specific closure design, with representative samples selected for testing.

    CCIT should generally be considered on a batch-by-batch basis, particularly as manufacturers accumulate testing data.

    However, based on the CCS and the specific container closure design, testing frequency may be reduced when sufficient justification is available.

    Nevertheless, testing frequency should not be reduced without careful consideration in situations such as:

    • Changes in the container closure system supply chain.

    • Products such as vacuum-sealed vials.

    It is important to note that the document does not require all packaging formats to use the same testing method, nor does it mandate 100% CCIT for every product.

    The testing strategy should be determined based on packaging design, closure method, associated risks, and validation results.

    4. Single-Use Systems (SUS): Supplier Test Reports Do Not Automatically Replace End-User Verification

    This section is particularly important for biopharmaceutical manufacturers, as well as users of single-use bioprocess bags and fluid transfer assemblies.

    With the increasing adoption of Single-Use Systems in biopharmaceutical manufacturing, system integrity, supplier quality management, and material compatibility have become important aspects of contamination control.

    PI 058-1 provides further clarification on these topics.

    1. If the Supplier Has Already Performed Integrity Testing, Does the End User Still Need to Conduct Testing?

    The document’s general position is that, where possible, critical Single-Use Systems should undergo integrity testing at the end user’s site.

    Testing may be performed before and/or after production use, depending on the risk of compromising product sterility.

    If a manufacturer chooses to rely on integrity test results provided by the supplier, a thorough risk assessment and supplier qualification assessment are required.

    These assessments should consider:

    • Whether the supplier’s testing method is reliable.

    • Whether testing covers the entire Single-Use System rather than only individual components.

    • Whether damage could occur during transportation, storage, or installation.

    • The potential impact of integrity defects on product quality and the manufacturing process.

    • Whether other in-process controls are available to detect potential defects.

    2. Is Pressure Hold Testing Suitable for Single-Use Systems?

    The document identifies pressure hold testing using an inert gas as one possible method for evaluating the integrity of Single-Use Systems.

    However, it also acknowledges that pressure hold testing can be difficult to implement for certain system designs and that the reliability of test results may have limitations.

    Therefore, the suitability of this method should be evaluated based on system design, testing capabilities, and associated risks.

    3. Can Validation Documentation Provided by Suppliers Be Accepted Directly?

    Supplier documentation can be used as supporting evidence, but it should not be accepted without review.

    Manufacturers need to thoroughly evaluate the validation documentation, material compatibility, and extractables and leachables (E&L) studies provided by suppliers.

    Particular attention should be paid to whether the supplier’s testing conditions adequately represent the manufacturer’s actual production conditions or worst-case scenarios.

    In addition, manufacturers should generally conduct on-site assessments of manufacturers of critical Single-Use Systems or obtain appropriate evidence of their compliance, and establish corresponding quality agreements.

    4. Integrity Testing of Single-Use Bags

    The document specifically mentions that, where technically feasible and required by the CCS, the integrity of Single-Use Systems should be verified through pressure hold testing.

    At the end-user site, detailed visual inspections should also be performed, including examinations of welds, connectors, scratches, and other defects that could potentially compromise system integrity.

    These requirements have practical implications for the quality control of single-use bioprocess bags, storage bags, mixing bags, and associated fluid transfer assemblies.

    Supporting Sterile Manufacturing Through Reliable Testing Technologies

    For manufacturers of sterile medicinal products, the publication of PI 058-1 provides clearer guidance for understanding and implementing key requirements of the 2022 version of Annex 1. It also highlights the continued focus of regulatory authorities on sterile manufacturing process control, contamination risk management, and product integrity assurance.

    From pharmaceutical water monitoring and sterilizing filtration to container closure integrity testing and Single-Use System management, these requirements ultimately share a common objective: to continuously monitor potential risks throughout the manufacturing process through scientific, reliable, and validated testing methods, thereby safeguarding product quality and patient safety.

    As a company specializing in the development and manufacturing of pharmaceutical testing instruments, Integridad médica will continue to follow developments in international pharmacopoeial standards and GMP regulations.

    We provide professional testing equipment across a range of applications, including Filter Integrity Testing, TOC Analysis, Container Closure Integrity Testing (CCIT), Glove Integrity Testing, Single-Use Bag Integrity Testing, Freezing-Point Osmometry, and Rapid Transfer Port (RTP) Integrity Testing.

    Through reliable testing technologies and professional support, MedIntegrity aims to help pharmaceutical manufacturers strengthen their quality control systems and address the compliance and quality management challenges associated with sterile manufacturing.

    Publicaciones relacionadas